MedTrace Logo

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

NCT06110793 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-05-13

No results posted yet for this study

Summary

The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.

Conditions

Interventions

DRUG

Lenvatinib

20mg orally PO daily

DRUG

Pembrolizuma

400mg IV Q6W

DRUG

Fulvestrant

500mg IM Q4W

Sponsors & Collaborators

Principal Investigators

  • Sherry Shen, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-29
Primary Completion
2027-11-30
Completion
2027-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06110793 on ClinicalTrials.gov